Although blockage of extracellular HMGB1 did not affect the systemic metabolic profiles, evidenced by hyperglycemia and glucose intolerance (Figure 7B), glycyrrhizin rescued cardiac function (Figures 7C and 7D; Table S5) and ameliorated cardiac pathological remodeling with reduced Nppb levels (Figures 7E, 7F, and S13). Here, HMGB1 is linked to Glucose intolerance.